According to Nova One Advisor, the global small molecule drug discovery outsourcing market size is expected to be worth around 13.43 billion by 2034, increasing from USD 5.67 billion in 2025, representing a healthy CAGR of 10.06% from 2025 to 2034.
The small molecule drug discovery outsourcing market is expanding due to it offers access to particular expertise, cost efficiency, and faster time. Outsourcing improves the quality of drug development by leveraging particular expertise and advanced technologies. It's vital to select reputable partners and preserve robust quality control measures during the process.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report@ https://www.novaoneadvisor.com/report/sample/9184
Small Molecule Drug Discovery Outsourcing Market Highlights:
• North America dominated the global small molecule drug discovery outsourcing market in 2024.
• Asia Pacific is expected to grow at the fastest CAGR over the forecast period.
• By workflow, the lead identification & candidate optimization segment dominated the market with the largest share in 2024.
• By workflow, the preclinical development segment is expected to grow significantly over the forecast period.
• By service, the chemistry services segment accounted for the highest market share in 2024.
• By service, the biology services segment is expected to show significant growth during the predicted timeframe.
• By therapeutic area, the respiratory system segment held the largest market share in 2024.
• By therapeutic area, the oncology segment is expected to show significant growth over the forecast period.
• By end-use, the pharmaceutical & biotechnology segment generated the highest market revenue in 2024.
• By end-use, the academic institutes segment is expected to register significant growth during the forecast period.
Market Overview and Industry Potential
The small molecule drug discovery outsourcing market is expanding due to it plays a significant role in the discovery of drugs in the early phase. This allows pharmaceutical companies to reach external knowledge and resources, which support them in speeding up research. Outsourcing organizations allow companies to meet the activity level based on the requirements of every project. It is particularly useful in the early stages of the discovery of the drug, where the outcomes are undefined and the projects often change direction.
Outsourcing continues to open a major of opportunities in the novel discovery of drug in the early phase, particularly it is more acceptable in pharmaceutical and biotechnological regions. This enables companies to detect novel drug goals and healthcare fields instead of advanced facilities or long-term employees. Outsourcing by merging internal potential along with external support offers a strategic and practical approach. When supported by the correct technologies and clear plans, it supports collaborative model organizations to strengthen research efforts and enhance the chances of offering efficient novel treatment to patients.
Buy Now Full Report: https://www.novaoneadvisor.com/report/checkout/9184
Latest Trends of the Market
⬥︎ In January 2025, Qualified Health announced its launch with $30 million in seed funding to develop the infrastructure for generative AI in healthcare. The major investors are SignalFire, Healthier Capital, Town Hall Ventures, and Frist Cressey Ventures, along with participation from Intermountain Ventures, Flare Capital Partners, and prominent healthcare and technology sector angels.
⬥︎ In April 2025, Flagship Pioneering, the bioplatform innovation company, unveiled Etiome, a company redefining how to detect and preempt disease progression. Etiome's Temporal Biodynamics platform is the first end-to-end technology to characterize disease with increased resolution over time and accelerate the development of preemptive medicines that promise advanced health results for people at risk of chronic or progressive diseases.
Recent Advancements in Technology: Market’s Largest Potential
Recent technological advancements in outsourcing services, such as the application of AI in the medical care industry, require healthcare institutions to adapt. These supports achieving more groundbreaking ways of streamlining processes and adapting advanced talents effectively. Outsourcing has become a strategic option for pharmaceutical companies looking to optimize their R&D processes and speed up time-to-market for novel drugs.
Pharmaceutical companies are increasing strategic partnerships with CROs to advance access to technologies for hastening drug development. Partnering with a CRO offers access to precision micro-dosing of small molecules that allows sponsors to move efficiently toward medical proof-of-concept, which drives the growth of the market.
⬥︎ For Instance, In April 2025, The Icahn School of Medicine at Mount Sinai launched the AI Small Molecule Drug Discovery Center, a bold endeavor that harnesses artificial intelligence (AI) to revolutionize drug development. The new Center will integrate AI with traditional drug discovery methods to identify and design new small-molecule therapeutics with unprecedented speed and precision.
Immediate Delivery Available | Buy This Premium Research https://www.novaoneadvisor.com/report/checkout/9184
Report Scope of Small Molecule Drug Discovery Outsourcing Market
|
Report Coverage |
Details |
|
Market Size in 2025 |
USD 13.43 Billion |
|
Market Size by 2034 |
USD 13.43 Billion |
|
Growth Rate From 2025 to 2034 |
CAGR of 10.06% |
|
Base Year |
2024 |
|
Forecast Period |
2025-2034 |
|
Segments Covered |
Workflow, Service, Therapeutics Area, End use, Region |
|
Market Analysis (Terms Used) |
Value (US$ Million/Billion) or (Volume/Units) |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Key Companies Profiled |
Albany Molecular Research (Curia), Charles River Laboratories, Dalton Pharma Services, Domainex, Dr. Reddy Laboratories Ltd., Eurofins, Evotec, GenScript Biotech,Jubilant Biosys, Laboratory Corporation of America Holdings (Covance), Merck & Co., Inc., Oncodesign, Pharmaceutical Product Development, LLC, Pharmaron, QIAGEN, Syngene International, TCG Lifesciences Pvt Ltd., WuXi AppTec |
Small Molecule Drug Discovery
Outsourcing Market Segmentation Analysis: By Lead Identification & Candidate
Optimization Analysis: The instruments segment dominates in the
small molecule drug discovery outsourcing market, as it helps enhance the
quality and quantity of leads, also offering greater access to professional
knowledge and skills. It cuts expenses and saves money over a period. It
increases efficiency, improves leads, provides access to commercial acumen, and
an ultimate uptick in sales. Outsourcing increases the recruitment process by
leveraging the provider's resources and expertise to rationalize workflows. On the other hand, the preclinical
development segment is expected to grow significantly during the forecast
period, as outsourcing pre-clinical CRO
services can lead to significant cost savings. Establishing and maintaining in-house
facilities and resources for preclinical development requires substantial
financial investment. Outsourcing preclinical studies can reduce development
timelines by up to 30% while ensuring compliance with GLP (Good Laboratory
Practice) standards. By Service Analysis: The chemistry services segment dominated
the market in 2024, as it improves efficiency, lowers costs, improves
compliance and safety, and provides greater expansion and sustainability
opportunities. It easily handles the storage, transportation, and delivery of
chemical products on behalf of the manufacturer. On the other hand, the biology services
segment is expected to grow at the fastest CAGR in the market during the
forecast period, as it becomes a progressively popular approach in biotech and
pharmaceutical organizations. Outsourcing offers access to specialized
expertise that may not be available in-house. Major contract
research organizations (CROs) employ scientists with wide experience in
biological services. As the biotech industry continues to evolve, outsourcing
is likely to play an increasingly significant role in advancing scientific
discoveries. By Therapeutic Area Analysis: The respiratory system segment dominated
the market in 2024, as these molecules offer advantages like huge oral
bioavailability, the capability to engage intracellular pathways, and adaptable
dosing regimens, making it applicable to a wide spectrum of respiratory
diseases On the other hand, the oncology
segment is expected to grow at the fastest CAGR in the market during
the forecast period, as their less molecular weight, so they penetrate cell
membranes and enter cells, permitting highly personalized
interactions that directly disrupt intracellular processes in tumors. It offers
targeted therapies to cancer patients and has proven highly efficiently. By end-use Analysis: The pharmaceutical
& biotechnology segment dominated the market in 2024, as it
provides productivity benefits such as access to novel technology, virtualized
expenses, and risk sharing. As pharmaceutical companies face growing cost
pressures and as the difficulty of drug candidates increases, they are turning
to outsourcing partners. It lowers the requirement for cost investments and
growing access to specialized technical expertise. On the other hand, the academic institutes
segment is expected to grow at the fastest CAGR in the market during the
forecast period, as outsourcing allows institutes to respond rapidly to
fluctuating requirements. Virtual assistants provide flexibility in managing
tasks and scale their support based on demand. This is particularly important
for institutions handling seasonal tasks, like enrollment periods or exam
preparation phases. Institutions outsource time-consuming administrative work
to virtual assistants and free up their core team to emphasize strategic
priorities. By Regional Insights Which Region Dominated the Small
Molecule Drug Discovery Outsourcing Market? North America dominated the small molecule
drug discovery outsourcing market in 2024, due to the presence largest number
of biotech companies worldwide, found in North America, which invests more than
$75 billion per year. Those investments are set to rise due to further
developments in the biotech sector, and shift from international-based to
home-grown services and manufacturing sites. Presence of major biopharma
companies such as Merck, AbbVie, Pfizer, Bristol Myers Squibb, and Johnson
& Johnson, which are major clients for outsourcing services. United States to continue growing its
innovation economy, it should enact stronger policies that support business
R&D and federal R&D. For instance, in 2024 U.S. will spend $193.39
billion in R&D, which will increase continuous demand for CRO and CDMO
partnerships, contributing to the growth of the market. Why Asia Pacific is the Fastest Growing
in the Small Molecule Drug Discovery Outsourcing Market? In Asia Pacific, major companies of this
region are increasingly opting for nearshoring, outsourcing to neighboring
countries, to decrease time zone differences, enhance communication, and take
advantage of cultural resemblances. This region is a fascinating world-renowned
organization that supports them in saving costs while delivering
advanced-quality products. Asia Pacific governments invested largely in
infrastructure to help the growing outsourcing, which contributes to the growth
of the market. Small Molecule Drug Discovery
Outsourcing Market Companies: • Albany Molecular Research (Curia) • Domainex • Eurofins • Evotec • GenScript Biotech • Jubilant Biosys • Laboratory Corporation of America
Holdings (Covance) • Merck & Co., Inc. • Oncodesign • Pharmaceutical
Product Development, LLC • QIAGEN • Syngene International • TCG Lifesciences Pvt Ltd. What is Going Around the Globe? ⬥︎ In July 2024, Innovent Biologics, Inc., a
world-class biopharmaceutical company that develops, manufactures and
commercializes high-quality medicines for the treatment of oncology,
cardiovascular and metabolic, autoimmune, ophthalmology, and other major
diseases, announced a strategic partnership with WeComput to jointly advance
the construction and improvement of Innovent Biologics' Artificial Intelligence
for Drug Discovery platform. ⬥︎ In May 2025, Peptone announced a partnership with
Evotec to accelerate and scale the creation of small-molecule IDP-targeted
treatments across diverse therapeutic areas. Through the collaboration, Peptone
will harness Evotec's drug discovery toolbox encompassing deep domain expertise
in oncology and immunology, extensive assay development know-how, and
state-of-the-art screening capabilities to seamlessly integrate with its
pioneering, physics-based approach to understanding IDP structural dynamics. You can place an order or ask any
questions, please feel free to contact at sales@novaoneadvisor.com |
+1 804 441 9344 Related Report – ⬥︎ Cell & Gene Therapy Contract Research Organizations Market - https://www.novaoneadvisor.com/report/cell-and-gene-therapy-contract-research-organizations-market
⬥︎ Cell And Gene Therapy CDMO Market- https://www.novaoneadvisor.com/report/cell-and-gene-therapy-cdmo-market
⬥︎ AI in Medical Imaging Market - https://www.novaoneadvisor.com/report/ai-in-medical-imaging-market
⬥︎ Cancer Vaccines Market - https://www.novaoneadvisor.com/report/cancer-vaccine-market
⬥︎ Regenerative Medicine Market - https://www.novaoneadvisor.com/report/regenerative-medicine-market-
⬥︎ U.S. Large And Small-scale Bioprocessing Market - https://www.novaoneadvisor.com/report/us-large-and-small-scale-bioprocessing-market
⬥︎ Implantable Medical Devices Market - https://www.novaoneadvisor.com/report/implantable-medical-devices-market
Segments Covered in the Report This report forecasts revenue growth at
country levels and provides an analysis of the latest industry trends in each
of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc.
has segmented the small molecule drug discovery outsourcing market. By Workflow • Lead Identification & Candidate
Optimization • Target Identification & Screening • Target Validation & Functional
Informatics • Preclinical Development •Others By Service • Biology Services • Chemistry Services By Therapeutic Area • Anti-infective • Cardiovascular • Central Nervous System • Dermatology • Endocrine • Gastrointestinal • Genitourinary System • Hematology • Immunomodulation • Oncology • Ophthalmology • Pain and Anesthesia • Respiratory system By End Use • Academic Institutes • Pharmaceutical & Biotechnology
companies By Regional • North America • Europe • Asia Pacific • Latin America • Middle East and Africa (MEA) Immediate Delivery Available | Buy This
Premium Research https://www.novaoneadvisor.com/report/checkout/9184
About-Us Nova One Advisor is a global leader
in market intelligence and strategic consulting, committed to delivering deep,
data-driven insights that power innovation and transformation across
industries. With a sharp focus on the evolving landscape of life sciences, we
specialize in navigating the complexities of cell and gene therapy, drug
development, and the oncology market, enabling our clients to lead in some of
the most revolutionary and high-impact areas of healthcare. Our expertise spans the entire
biotech and pharmaceutical value chain, empowering startups, global
enterprises, investors, and research institutions that are pioneering the next
generation of therapies in regenerative medicine, oncology, and precision
medicine. Web: https://www.novaoneadvisor.com/ Contact Us USA: +1 804 420 9370 Email: sales@novaoneadvisor.com For Latest Update
Follow Us: LinkedIn
